Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAYA study of temozolomide lead-in followed by nivolumab + ipilimumab + temozolomide in MSS, MGMT-silenced metastatic colorectal cancer
2018-004299-37Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab, ipilimumab and temozolomide in colorectal cancer (CRC), metastatic colorectal adenocarcinoma (mCRC) and microsatellite stable colorectal cancer, sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: 8-month progression-free survival rate. Started Dec 2020; status: completed.
02
Drugs
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)microsatellite stable colorectal cancer
Beyond the preview
Go deeper on 2018-004299-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004299-37.